Tandem Diabetes Care (NASDAQ:TNDM) Issues Earnings Results, Beats Expectations By $0.15 EPS

Tandem Diabetes Care (NASDAQ:TNDM) announced its quarterly earnings results on Thursday. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.15, FiscalAI reports. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The firm had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. During the same period in the prior year, the firm earned ($0.31) EPS. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year.

Here are the key takeaways from Tandem Diabetes Care’s conference call:

• Q3 results were strong: worldwide revenue rose 14% to $284 million and pump shipments increased 12%, while gross margin reached 57% and adjusted EBITDA margin was 6%. Tandem maintained its 2026 sales guidance of $1.065 billion–$1.085 billion.
• Pharmacy adoption is progressing more slowly than expected, though formulary coverage reached about 50% and recurring supply economics exceeded baseline expectations. Tandem expects the transition to weigh on sales into 2027 and said mid- to high-single-digit revenue growth is a reasonable starting point for next year.
• International sales rose 26% to a record $93 million, supported by product launches and stronger direct-market performance. Tandem plans to expand direct operations to cover roughly half of its international installed base by the end of 2027.
• Product development could broaden Tandem’s market opportunity: Mobi Tubeless is in late-stage FDA review, with commercial availability targeted for the first half of 2027 if cleared. The company also plans to begin a pivotal trial of its fully closed-loop system by year-end 2026, with a potential launch in 2028.

Tandem Diabetes Care Stock Down 6.5%

Tandem Diabetes Care stock traded down $1.17 during midday trading on Friday, hitting $16.82. 1,420,908 shares of the stock were exchanged, compared to its average volume of 2,132,735. Tandem Diabetes Care has a 1 year low of $12.26 and a 1 year high of $29.65. The firm has a market cap of $1.17 billion, a P/E ratio of -18.04 and a beta of 1.59. The company has a debt-to-equity ratio of 4.62, a current ratio of 3.18 and a quick ratio of 2.65. The company has a 50 day moving average price of $17.74 and a two-hundred day moving average price of $18.90.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. William Blair began coverage on Tandem Diabetes Care in a research note on Friday, August 21st. They set an “outperform” rating on the stock. Oppenheimer reiterated an “outperform” rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. Mizuho set a $20.00 target price on Tandem Diabetes Care in a report on Friday. Finally, Truist Financial reduced their price target on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $27.08.

Tandem Diabetes Care News Summary

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q3 revenue was $283.7 million, up 13.8% year over year and above analyst estimates of $265.9 million. The company’s loss of $0.10 per share was also narrower than expected. Tandem Q3 2026 financial results
• Positive Sentiment: Gross margin improved to 57%, up 2.7 percentage points from a year earlier. Tandem also reported about 33,000 pump shipments, supporting evidence of business growth. Tandem Q3 2026 financial results
• Positive Sentiment: Management forecast 2026 sales of $1.065 billion to $1.085 billion, giving investors a full-year revenue range to assess against the company’s growth trajectory. 2026 sales outlook and CEO transition
• Neutral Sentiment: Tandem named Jeannette Bankes as president and CEO as John Sheridan plans to retire at the end of 2026. Naming a successor provides advance notice, though investors may watch for details on strategic continuity during the transition. Tandem names Jeannette Bankes CEO

Insider Buying and Selling

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares of the company’s stock, valued at $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by corporate insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.